title: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.
abstract: METHODS
  Although their clinical efficacy is unclear and they may cause serious adverse effects, systemic glucocorticoids are a standard treatment for patients hospitalized with exacerbations of chronic obstructive pulmonary disease (COPD). We conducted a double-blind, randomized trial of systemic glucocorticoids (given for two or eight weeks) or placebo in addition to other therapies, for exacerbations of COPD. Most other care was standardized over the six-month period of follow-up. The primary end point was treatment failure, defined as death from any cause or the need for intubation and mechanical ventilation, readmission to the hospital for COPD, or intensification of drug therapy.
  
  
  RESULTS
  Of 1840 potential study participants at 25 Veterans Affairs medical centers, 271 were eligible for participation and were enrolled; 80 received an eight-week course of glucocorticoid therapy, 80 received a two-week course, and 111 received placebo. About half the potential participants were ineligible because they had received systemic glucocorticoids in the previous 30 days. Rates of treatment failure were significantly higher in the placebo group than in the two glucocorticoid groups combined at 30 days (33 percent vs. 23 percent, P=0.04) and at 90 days (48 percent vs. 37 percent, P=0.04). Systemic glucocorticoids (in both groups combined) were associated with a shorter initial hospital stay (8.5 days, vs. 9.7 days for placebo, P=0.03) and with a forced expiratory volume in one second that was about 0.10 liter higher than that in the placebo group by the first day after enrollment. Significant treatment benefits were no longer evident at six months. The eight-week regimen of therapy was not superior to the two-week regimen. The patients who received glucocorticoid therapy were more likely to have hyperglycemia requiring therapy than those who received placebo (15 percent vs. 4 percent, P=0.002).
  
  
  CONCLUSIONS
  Treatment with systemic glucocorticoids results in moderate improvement in clinical outcomes among patients hospitalized for exacerbations of COPD. The maximal benefit is obtained during the first two weeks of therapy. Hyperglycemia of sufficient severity to warrant treatment is the most frequent complication.
authors.affiliation: Veterans Affairs Medical Center in Minneapolis, MN 55417, USA. niewo001@maroon.tc.umn.edu
authors.forename: D E
authors.initials: DE
authors.lastname: Niewoehner
authors.forename: M L
authors.initials: ML
authors.lastname: Erbland
authors.forename: R H
authors.initials: RH
authors.lastname: Deupree
authors.forename: D
authors.initials: D
authors.lastname: Collins
authors.forename: N J
authors.initials: NJ
authors.lastname: Gross
authors.forename: R W
authors.initials: RW
authors.lastname: Light
authors.forename: P
authors.initials: P
authors.lastname: Anderson
authors.forename: N A
authors.initials: NA
authors.lastname: Morgan
mesh_terms: D000284:Administration, Oral; D000368:Aged; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005541:Forced Expiratory Volume / Q000187:drug effects; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D007262:Infusions, Intravenous; D007902:Length of Stay; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008775:Methylprednisolone / Q000009:adverse effects / Q000627:therapeutic use; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D005938:Glucocorticoids; D011241:Prednisone; D008775:Methylprednisolone